The prospectus is not for release, publication or distribution, directly or indirectly, in or into the United States, Canada, Japan or Australia or any other jurisdiction in which such release, publication or distribution would be unlawful.

Neither the delivery of the prospectus nor the issue, sale or delivery of any note shall, in any circumstances, create any implication that the information contained in the prospectus is true subsequent to the date thereof or, if the prospectus is supplemented after the date thereof, the date of the relevant supplement or that there has been no adverse change, or any event reasonably likely to involve any adverse change, in the prospects or financial or trading position of Novo Nordisk A/S since the date thereof or, if the prospectus is supplemented after the date thereof, the date of the relevant supplement or that any other information supplied in connection with the notes is correct at any time subsequent to the date on which it is supplied or, if different, the date indicated in the document containing the same.

The prospectus is not intended to provide the basis of any credit or any other evaluation and should not be considered as a recommendation by Novo Nordisk A/S that any recipient of the prospectus should invest in the notes. Prospective investors should make an independent assessment as to whether the information in the prospectus is relevant to their situation, and any investment in the notes should be based on the information regarding the investor's specific circumstances that the investor may deem necessary and only if the notes are consistent with the investor’s financial objectives.

The distribution of the prospectus and the offering or sale of notes in certain jurisdictions may be restricted by law. The prospectus may not be distributed or otherwise made available and the notes may not be offered or sold, directly or indirectly, in any jurisdiction, unless such distribution, offering or sale is permitted under applicable laws in the relevant jurisdiction.

The notes have not been and will not be registered under the United States Securities Act of 1933, as amended (the "Securities Act") and may not be offered or sold within the United States or to, or for the account or benefit of, U.S. persons except in certain transactions exempt from the registration requirements of the Securities Act.

References above to the “prospectus” are to the prospectus as supplemented from time to time.